Bernstein raised Eli Lilly’s price target to $1,300 from $1,100, citing upcoming GLP-1 catalysts. Analyst Courtney Breen believes Lilly’s next wave of catalysts could drive significant growth. Breen, with a 94% success rate, sees a setup offering substantial upside. Lilly’s trillion-dollar club entry may just be the beginning of its momentum.

Breen’s bullishness on Eli Lilly stems from a rich catalyst path, notably oral GLP-1 drug orforglipron. U.S. policy changes and global reimbursement channels are expected to boost sales. Breen’s financial model shows consensus is undervaluing Lilly’s potential sales. 2026 is projected to be a breakthrough year for Lilly’s weight-loss drugs.

The science behind GLP-1 weight loss drugs involves reducing hunger signals and slowing stomach emptying. These drugs mimic gut hormones that signal fullness, leading to steady weight loss. The weight-loss drug market is expected to grow significantly, with branded obesity drugs generating billions in revenue by 2030.

Eli Lilly’s weight-loss breakthrough has propelled it to the trillion-dollar club. The success is driven by tirzepatide’s dominance and a robust pipeline. Record-breaking GLP-1 sales in Q3 2025 and strong financial performance have attracted investors. With an oral GLP-1 drug on the horizon, Lilly’s growth trajectory remains strong.

Lilly’s future success hinges on orforglipron’s Phase 3 data, positioning the company to lead the GLP-1 market. The company’s tech-style profitability, expanding market reach, and strong financial performance indicate a promising future. This news was originally published by TheStreet on Nov 25, 2025.

Read more at Yahoo Finance: Top analyst drops jaw-dropping price target on Eli Lilly stock